Drug or technology

RNA, Messenger

3 developments in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

Latest

Everything in the corpus, newest first.

AUG 12, 2026 · JOURNAL ARTICLE

Targeted delivery of mRNA to immune cells for in vivo cell therapy.

Drug Delivery

A comprehensive review article synthesizing current knowledge on mRNA delivery engineering strategies to immune cells, identifying translational barriers and technical advances rather than reporting original experimental results or clinical outcomes.

Expert GuidanceNanoparticles Jinfeng Deng Yumin Li

Reported

Ex vivo CAR-T manufacturing durat…typically 3–4 weeks

JUL 7, 2026 · JOURNAL ARTICLE

Lymph node-targeted mRNA delivery of fine-tuned peptide-nanocomplexes for SARS-CoV-2 Vaccination.

Biomaterials

Preclinical mouse study demonstrates a novel peptide-nanocomplex delivery system with improved lymph node targeting and prolonged antigen expression compared to lipid nanoparticles, with comparable neutralizing antibody responses and superior CD8+ T cell responses, but lacks human data and clinical validation.

PromisingNanoparticles Dong Woo Lee Hayoon Jeong

Reported

Particle sizeunder 200 nm

Duration of mRNA expression (pept…up to 7 days

Duration of mRNA expression (LNPs)within 48 h

JUN 16, 2026 · JOURNAL ARTICLE

Preventive and therapeutic efficacy of mRNA/LNP vaccines encoding HPV16 E6 and E7 in an early-intervention HPV tumor mouse models.

Human Vaccines & Immunotherapeutics

Preclinical murine tumor model study demonstrating HPV16 E7 mRNA/LNP vaccine efficacy in early-intervention setting, with no human data or comparator arm against standard therapy.

PreliminaryNanoparticles Kittipan Tharakhet Chutitorn Ketloy

Reported

Tumor inoculum size5,000–10,000 TC-1 cells

E7 dose (low, single intramuscula…1 µg

Therapeutic E7 dose (single or fi…10 µg